Preference for Immunotherapy with Tablets by People with Allergic Rhinitis

Tankersley, Mike; Winders, Tonya; Aagren, Mark; Brandi, Henrik; Pedersen, Mikkel H; Loftager, Anne Sofie Ledgaard; Bøgelund, Mette

doi:10.2147/ppa.s338337

Cited by 9 publications

(14 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results confirm the findings from a similar study conducted in the US. Respondents included in the US study showed comparable preferences for AIT administered as tablets and for reductions in the risk of systemic reactions 25 …”

Section: Discussionmentioning

confidence: 99%

“…Respondents included in the US study showed comparable preferences for AIT administered as tablets and for reductions in the risk of systemic reactions. 25 …”

Section: Discussionmentioning

confidence: 99%

“…As the survey used in this study have also been used in a similar study carried out in the US, 25 the survey was already tested. Therefore, no pilot was carried out in Spain.…”

Section: Methodsmentioning

confidence: 99%

“…Respondents included in the US study showed comparable preferences for AIT administered as tablets and for reductions in the risk of systemic reactions. 25 SLIT-tablets constitute a smaller share of the prescribed AIT in Spain compared to SCIT. More specifically, SCIT was in 2015 used for 85.5% of the adults and 77.8% of the children in Spain.…”

Section: Subgroup Analysesmentioning

confidence: 97%

See 3 more Smart Citations

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Bøgelund¹,

Rosado

Ruiz³

et al. 2022

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

Background This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy‐tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective. Methods A discrete choice experiment (DCE) consisting of two blocks with eight choice sets in each was constructed to elicit the preferences for AIT. Three attributes were included in the DCE for the mode of administration, including the frequency of administration, the risk of systemic reactions and the co‐payment. Adults and caregivers of children with moderate to severe allergic rhinitis (AR) were included if they were not currently receiving or had not previously received AIT. Results In total, 587 adults and 613 caregivers started the survey. Of those, 579 adults and 611 caregivers completed the survey and were included in the study. Both adults and caregivers had a significant preference for tablets compared with both monthly and weekly injections ( p ≤ 0.0001). Furthermore, the respondents showed a significant preference for reducing the risk of systemic reactions. Subgroup analyses showed that caregivers of polyallergic children and female caregivers were significantly less price sensitive when choosing their preferred treatment. Conclusion Our study demonstrated that both adults with AR and caregivers of children with AR prefer daily SLIT‐tablets to SCIT with either a weekly or monthly dose schedule.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Respondents included in the US study showed comparable preferences for AIT administered as tablets and for reductions in the risk of systemic reactions. 25 …”

Section: Discussionmentioning

confidence: 99%

“…As the survey used in this study have also been used in a similar study carried out in the US, 25 the survey was already tested. Therefore, no pilot was carried out in Spain.…”

Section: Methodsmentioning

confidence: 99%

Section: Subgroup Analysesmentioning

confidence: 97%

See 2 more Smart Citations

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Bøgelund¹,

Rosado

Ruiz³

et al. 2022

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

show abstract

“…SLIT is also considered to be safer than SCIT [ 14 , 15 ]. Studies and patient surveys indicate that patients have a strong preference for SLIT over SCIT because of the convenience of at home administration and the more favorable safety profile [ 16 – 19 ]. For the same reasons, these preferences also translate to caregivers of children receiving AIT [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis

Ellis

Mack

Gagnon³

et al. 2023

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background Allergy immunotherapy (AIT), in the form of subcutaneous immunotherapy (SCIT) with alum-precipitated aqueous extracts, SCIT with a modified ragweed pollen allergen tyrosine adsorbate (MRPATA; Pollinex®-R), or a sublingual immunotherapy (SLIT)-tablet are options for the treatment of ragweed pollen allergic rhinoconjunctivitis (ARC) in Canadian children. A cost minimization analysis evaluated the economic implications of the use of the ragweed SLIT-tablet vs SCIT in Canadian children with ragweed ARC. Methods A cost minimization analysis was conducted comparing the short ragweed SLIT-tablet, 12 Amb a 1-U, preseasonally with preseasonal ragweed SCIT, annual ragweed SCIT, or MRPATA. The analysis was conducted over a time horizon of 3 years from a public payer perspective in Ontario and Quebec. Resources and costs associated with medication and services of healthcare professionals were considered for each treatment. The resource and cost input values for the model were obtained from published literature and validated by Canadian clinical experts in active allergy practice. A discount rate of 1.5% was applied. Several scenario analyses were conducted to determine the impact of many of the key base case assumptions on the outcomes. Results Over the total 3-year time horizon, the ragweed SLIT-tablet had a potential cost savings of $900.14 in Ontario and $1023.14 in Quebec when compared with preseasonal ragweed SCIT, of $6613.22 in Ontario and $8750.64 in Quebec when compared with annual ragweed SCIT, and $79.62 in Ontario and $429.49 in Quebec when compared with MRPATA. The ragweed SLIT-tablet had higher drug costs compared with the other AIT options, but lower costs for healthcare professional services. The lower costs for healthcare professional services with the ragweed SLIT-tablet were driven by the need for fewer office visits than SCIT. Scenario analysis indicated that costs were most impacted by including societal costs (e.g., costs associated with patient/caregiver travel and time lost). The potential cost savings of the ragweed SLIT-tablet versus SCIT and MRPATA was maintained in most scenarios. Conclusions In this cost minimization analysis, the ragweed SLIT-tablet provided estimated cost savings from a public payer perspective for the treatment of ragweed ARC in Canadian children compared with SCIT or MRPATA.

show abstract

Preference Phenotypes in Thyroid Nodule Management: A Patient Segmentation Approach

Naunheim,

Wasserman,

von Sneidern

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

ObjectivePatient preferences regarding thyroid nodules are poorly understood. Our objective is to (1) employ a discrete choice experiment (DCE) to explore risk tradeoffs in thyroid nodule management, and (2) segment respondents into preference phenotypes.Study DesignDCE.SettingThyroid surgery clinic, online survey.MethodsA DCE including 5 attributes (cancer risk, voice concerns, incision/scar, medication requirement, follow‐up frequency) was refined with qualitative patient and physician input. A final DCE including 8 choice tasks, demographics, history, and risk tolerance was administered to participants with and without thyroid disease. Analysis was performed with multinomial logit modeling and latent class analysis (LCA) for preference phenotyping.ResultsA total of 1026 respondents were included; 480 had thyroid disease. Risk aversion was associated with increasing age (P < .001), female gender (P < .001), and limited education (P = .038), but not previous thyroid disease. Cancer risk most significantly impacted decision‐making. Of the total possible utility change from thyroid nodule decision‐making, 47.8% was attributable to variations in cancer risk; 20.0% from medication management; 14.9% from voice changes; 12.7% from incision/scar; and 4.6% from follow‐up concerns. LCA demonstrated 3 classes with distinct preference phenotypes: the largest group (64.2%) made decisions primarily based on cancer risk; another group (18.2%) chose based on aversion to medication; the smallest group (17.7%) factored in medication and cancer risk evenly.ConclusionCancer risk and the need to take medication after thyroid surgery factor into patient decision‐making most heavily when treating thyroid nodules. Distinct preference phenotypes were demonstrated, reinforcing the need for individual preference assessment before the treatment of thyroid disorders.

show abstract

Preference for Immunotherapy with Tablets by People with Allergic Rhinitis

Cited by 9 publications

References 33 publications

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis

Preference Phenotypes in Thyroid Nodule Management: A Patient Segmentation Approach

Contact Info

Product

Resources

About